Drug intelligence / Profile preview

abiraterone + prednisone + enzalutamide + apalutamide + rezvilutamide

Development stage: Unknown
Lead developer: Janssen Biotech
Modality: Small Molecules
Administration: Oral

Overview

This is a combination therapy consisting of multiple anti-androgen agents (abiraterone, enzalutamide, apalutamide, rezvilutamide) plus prednisone. Abiraterone acetate is a CYP17A1 inhibitor that blocks androgen biosynthesis and is typically administered with prednisone to prevent mineralocorticoid excess-related adverse events. Enzalutamide, apalutamide, and rezvilutamide are androgen receptor inhibitors. This combination represents an intensive approach to androgen deprivation therapy for prostate cancer treatment.

Targets

CYP17A1 (Steroid 17-alpha-hydroxylase/C17,20 lyase)GR (Glucocorticoid receptor)AR (Adrenergic receptors)

Beyond the preview

Go deeper on abiraterone + prednisone + enzalutamide + apalutamide + rezvilutamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on abiraterone + prednisone + enzalutamide + apalutamide + rezvilutamide.

Explore the full profile